Tuftsin Guide 2026: TKPR Peptide, NRP-1 & Evidence

Tuftsin Guide 2026: TKPR Peptide, NRP-1 & Evidence
Educational use only. This article is informational and does not constitute medical advice. Peptide dosing decisions should be made in consultation with a licensed physician familiar with your medical history. Always verify any dose with your prescribing physician before drawing or administering. Some peptides discussed are not FDA-approved for human use; legal and regulatory status varies by jurisdiction.

Quick Answer

Tuftsin is a four-amino-acid peptide (Thr-Lys-Pro-Arg, abbreviated TKPR) that is released from the CH2 domain of the IgG heavy chain by two enzymes, one in the spleen, one on the phagocyte surface. It was discovered in 1970 at Tufts University and named for the institution. Tuftsin binds neuropilin-1 (NRP-1) on macrophages and microglia and signals through the TGF-β pathway to enhance phagocytosis and shift macrophages toward an anti-inflammatory M2 phenotype.

Table of Contents

Regulatory status (June 2026): Tuftsin is not FDA-approved for any indication. There are zero studies registered on ClinicalTrials.gov. The most recent published human therapeutic trial is from 1987. The synthetic peptide sold by chemical suppliers is labeled “for laboratory research use only, not for human consumption.” Tuftsin is not on the FDA 503A Bulks List and was not among the 12 peptides FDA removed from Category 2 on April 15, 2026.

Bottom line: Tuftsin has a remarkable 55-year preclinical biology and a clinical record that is essentially empty. Strong mechanism, thin human data. The 2025 Science Translational Medicine “BATMAN” nanoparticle paper is the most credible translational tuftsin work in a generation, but it is still preclinical.


What Is Tuftsin?

Tuftsin is a linear, all-L tetrapeptide with the sequence Thr-Lys-Pro-Arg (one-letter code: TKPR). It is one of the smallest bioactive peptides in the immunology canon, with a molecular formula of C21H40N8O6 and a molecular weight of approximately 500.6 Da. The CAS Registry Number for the free peptide is 9063-57-4; the diacetate salt commonly supplied for research is CAS 72103-53-8. PubChem catalogs the molecule under CID 156080.

The peptide was isolated and named by Victor A. Najjar and Kazumasa Nishioka at Tufts University School of Medicine in Boston, and reported in Nature in 1970 (Najjar VA, Nishioka K. Nature. 1970;228(5272):672–3. PMID 4097539). The name “tuftsin” honors Tufts University, the institution where the discovery was made, a naming convention shared by very few peptides in the bioactive-peptide literature (Wardowska A, Dzierzbicka K, Myśliwski A. Postepy Biochem. 2007;53(1):60–5. PMID 17718389).

Origin in the IgG molecule

Tuftsin is not a synthetic invention. It is an endogenous fragment of immunoglobulin G. Modern primary literature places it at residues 289–292 of the CH2 domain of the IgG heavy chain Fc region. A more recent confirmation, a tuftsin-tailored fusion-protein paper from 2023, describes tuftsin as “a tetrapeptide located at residues 289–292 of the CH2 domain of the Fc region of the IgG heavy chain” (Yuan D et al., Biochem Biophys Rep. 2023;34:101443. PMID 36875797). Older sources sometimes give the position as 288–291; this reflects an earlier Kabat/Eu numbering convention. The 289–292 position is the modern consensus.

The peptide is liberated from its IgG carrier by two distinct enzymes acting sequentially:

  1. Splenic tuftsin endocarboxypeptidase cleaves the Arg-Glu bond on the C-terminal side, releasing a larger IgG fragment that Najjar termed leukokinin.
  2. Leukokininase, a membrane-bound enzyme on the outer surface of neutrophils, monocytes, and macrophages, cleaves the Lys-Thr bond on the N-terminal side, releasing the free TKPR tetrapeptide at the phagocyte surface (Najjar VA. Med Biol. 1981;59(3):134–8. PMID 6895538; Martinez J, Laur J, Winternitz F. Int J Pept Protein Res. 1983;22(1):119–24. PMID 6885245).

Because the C-terminal liberating step happens in the spleen, splenectomy or functional hyposplenism causes acquired tuftsin deficiency. This is the mechanistic reason that asplenic patients, including those with sickle-cell disease or surgically removed spleens, show defective phagocytic function beyond what intact serum IgG levels would predict.

Tuftsin is endogenously present in healthy human serum at low concentrations (reported ranges around 200–500 ng/mL). It is, by definition, a natural product, every healthy person makes it.

Tuftsin is not Selank

Readers searching for “tuftsin” frequently encounter dosing protocols and intranasal-use lore that actually belong to Selank, a Russian-developed heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) that extends tuftsin’s biological half-life by adding a C-terminal Pro-Gly-Pro tail. Selank has its own pharmacology, its own (Russian) marketing authorization as an intranasal anxiolytic, and is not interchangeable with native tuftsin. Selank dosing schedules (typically 250–900 mcg intranasally) are not transferable to native TKPR. Anywhere this guide mentions tuftsin, it means parent tuftsin (TKPR, CAS 9063-57-4), not Selank, not Selank Pro-Gly-Pro variants, and not any of the conjugates and fusion proteins discussed below.


Mechanism of Action

Neuropilin-1 (NRP-1) is the modern receptor

For decades, the existence of a discrete tuftsin receptor was inferred from saturable, high-affinity binding studies on neutrophils and macrophages, with macrophage Kd values reported around 53 nM and roughly 72,000 binding sites per cell (Bar-Shavit Z et al. Ann NY Acad Sci. 1983. PMID 6201115; Gottlieb P, Hazum E, Tzehoval E et al. Biochem Biophys Res Commun. 1984;119(1):203–11. PMID 6322775; Bump N, Lee J, Wleklik M et al. Proc Natl Acad Sci USA. 1986;83:7187–91. PMID 3463958). These classical papers documented binding, internalization, and partial receptor purification, but stopped short of assigning a defined gene or protein identity.

The modern molecular identity was established by the Tsirka lab at Stony Brook in 2013:

Nissen JC, Selwood DL, Tsirka SE. Tuftsin signals through its receptor neuropilin-1 via the transforming growth factor beta pathway. J Neurochem. 2013;127(3):394–402. PMID 24033337.

Key findings: the small-molecule NRP-1 antagonist EG00229 blocks biotinylated tuftsin binding to microglia in a dose-dependent fashion; EG00229 also reverses the tuftsin-induced anti-inflammatory M2 microglial polarization measured by qRT-PCR of TNF-α (M1 marker) and IL-10 (M2 marker); blocking TGF-β receptor 1 (TβR1), an NRP-1 coreceptor, similarly disrupts the M2 shift; tuftsin promotes Smad3 phosphorylation (canonical TGF-β signaling) and TGF-β release from microglia. The net coupling is tuftsin → NRP-1 → TβR1 → Smad3 → TGF-β release → M2 polarization, with autocrine TGF-β amplification.

In-vivo confirmation that microglial NRP-1 is required for tuftsin’s effect came in 2016, in the conditional NRP-1-microglia-knockout (Nrp1-MgKO) mouse: ablating microglial NRP-1 abolished tuftsin’s clinical benefit in the experimental autoimmune encephalomyelitis (EAE) model (Nissen JC, Tsirka SE. Glia. 2016;64(6):923–36. PMID 26880314).

Downstream biological effects

The verified mechanistic chain produces several downstream effects:

  • Enhanced phagocytosis. The defining activity, documented in the original 1970 paper (PMID 4097539) and reaffirmed across five decades of work.
  • M2 macrophage / microglial polarization. Via NRP-1 → TβR1 → Smad3 → TGF-β release. Documented in vitro (PMID 24033337) and in vivo (PMID 26880314).
  • Cytokine modulation. TNF-α decreases and IL-10 increases in microglia exposed to tuftsin (PMID 24033337).
  • Nitric oxide induction. Tuftsin synergizes with IFN-γ to induce iNOS in macrophages and drives nitric oxide-dependent killing of intracellular pathogens. This effect is reversed by L-NMMA and by dexamethasone, consistent with classical iNOS biology (Cillari E, Arcoleo F, Dieli M et al. Infect Immun. 1994. PMID 8188392). The same paper established the anti-Leishmania mechanism.
  • Receptor-mediated endocytosis kinetics. Surface clustering within 5 minutes, internalization at 5–30 minutes, receptor upregulation in the first 5–7 minutes followed by downregulation at 10–15 minutes (PMID 6322775).
  • Remyelination support in CNS demyelination models. M2 microglia clear myelin debris; tuftsin synergizes with benztropine in mouse demyelination models (PMID 30555470; Bao Z, Hao J, Li Y, Feng F. 2019. PMID 31702807).

Cell types affected

Tuftsin’s primary cellular targets are macrophages, microglia, neutrophils/PMNs, monocytes, and natural killer cells. The receptor density is highest on tissue macrophages and microglia, consistent with NRP-1 expression.

An honest mechanistic caveat, M2 versus M1

Tuftsin’s canonical effect via NRP-1/TGF-β is M2 polarization. This direction is desirable in neuroinflammation (multiple sclerosis, EAE, demyelinating disease, and, by extrapolation only, Alzheimer’s disease). However, tumor-associated macrophages (TAMs) in most solid tumors are already predominantly M2, and the therapeutic goal in tumor immunology is usually M2-to-M1 repolarization. This means naked tuftsin, applied to a solid tumor, would be expected to worsen the TAM phenotype rather than improve it.

The “tuftsin for cancer” framing that appears in vendor copy and forum posts therefore rests almost entirely on engineering: tuftsin-decorated nanoparticles, tuftsin-tailored fusion proteins, and tuftsin-bearing liposomes that exploit TKPR’s macrophage-targeting (FcγR plus NRP-1 binding) while delivering a pro-M1 cytotoxic payload. Native tuftsin as a monotherapy is not a credible solid-tumor agent based on its receptor biology.


Preclinical Evidence

The strongest body of preclinical work clusters around three areas: antimicrobial defense, CNS neuroinflammation, and modern nanomedicine.

Antimicrobial defense

Because free native tuftsin has a plasma half-life on the order of seconds-to-minutes, most antimicrobial efficacy data come from liposome-grafted or analog forms, primarily from the Owais group at Aligarh and Israeli/Indian collaborators:

  • Tuberculosis (mice). Rifampin encapsulated in tuftsin-bearing liposomes reduced lung bacillary load by more than 2,000-fold versus free rifampin at the same twice-weekly dose. Importantly, pretreatment with drug-free tuftsin liposomes did not confer resistance, the antimicrobial benefit required the drug payload. The tuftsin moiety acted as a macrophage-targeting ligand, not as a stand-alone bactericidal agent (Agarwal A, Sharma S, Khuller GK. Antimicrob Agents Chemother. 1994;38:588–93).
  • Candida albicans (leukopenic mice). Liposomized tuftsin plus fluconazole improved survival versus free fluconazole (Khan A, Owais M et al. FEMS Pathog Dis. 2006;46:63).
  • Cryptococcus neoformans (leukopenic BALB/c). Tuftsin-incorporated nystatin liposomes improved outcomes (FEMS Pathog Dis. 2012;66:88).
  • Anti-Leishmania via macrophage iNOS. Tuftsin-induced nitric oxide from macrophages kills Leishmania amastigotes; the effect requires LPS priming and is potentiated by IFN-γ (Cillari E, Arcoleo F, Dieli M et al. Infect Immun. 1994. PMID 8188392).

A common thread across the antimicrobial literature: tuftsin’s value is as a macrophage-targeting ligand on a delivery vehicle, not as an antimicrobial in its own right.

Antitumor activity, modest, adjuvant only

The antitumor literature is consistent on one point: effects are modest and almost always require a chemotherapy partner or a delivery vehicle.

  • Modest activity has been reported in murine L1210 leukemia and Cloudman S-91 melanoma models, attributed to macrophage, NK-cell, and granulocyte activation rather than direct cytotoxicity (Catane R et al. Ann NY Acad Sci. 1983;419:251–60. PMID 6370073).
  • Tuftsin inhibited disease development in a Rauscher virus leukemia mouse model (Knyszynski A, Gottlieb P, Fridkin M. PMID 6575215).
  • A tuftsin-tailored fusion protein enhanced macrophage phagocytosis of circulating gastric tumor cells and downregulated tumor CD47 (“don’t eat me” signal) in preclinical work (Yuan D et al. Biochem Biophys Rep. 2023. PMID 36875797).
  • A tuftsin-derivative (“T peptide”) designed to overcome the stability problem showed antitumor activity and improved pharmacokinetics in beagles (Gu R, He Y, Han S et al. Drug Metab Pharmacokinet. 2016. PMID 26775850).

Honest read: No mouse model produces dramatic monotherapy regression of the kind seen with checkpoint inhibitors. The literature is enriched with “tuftsin augments cyclophosphamide / etoposide / amphotericin” papers rather than stand-alone successes. This is consistent with the receptor biology and with the M2-direction caveat above.

Experimental autoimmune encephalomyelitis (EAE), the strongest modern signal

The Tsirka lab at Stony Brook has built the deepest modern preclinical record for tuftsin in any indication:

  • Tuftsin shifts microglia toward an M2 phenotype and improves clinical EAE scores in mice (Wu M, Nissen JC, Chen EI, Tsirka SE. PLoS One. 2012;7(4):e34933. PMID 22529957).
  • Macrophage inhibitory factor (TKP) and tuftsin (TKPR) attenuate EAE disease course (Bhasin M, Wu M, Tsirka SE. BMC Immunol. 2007;8:10. PMID 17634104).
  • NRP-1 mechanism established (PMID 24033337) and conditional microglial NRP-1 knockout abolishes the effect (PMID 26880314, Nissen JC, Tsirka SE).
  • Tuftsin combined with benztropine improves outcomes in demyelinating disease models (Thompson KK, Nissen JC, Tsirka SE. Front Immunol. 2018;9:2784. PMID 30555470).
  • Tuftsin promotes microglial phagocytosis and remyelination in EAE (Bao Z, Hao J, Li Y, Feng F. 2019. PMID 31702807).

This is preclinical work. No registered clinical trial of tuftsin in multiple sclerosis or any demyelinating disease has been identified.

Inferred relevance to Alzheimer’s disease is biologically plausible, NRP-1, M2 microglia, and TGF-β1 all sit on well-trodden AD biology pathways, but direct AD or PD model efficacy studies of native tuftsin are not well-supported in primary literature. Most “tuftsin for Alzheimer’s” framing in secondary sources extrapolates from EAE/demyelination work without a primary tuftsin-in-APP/PS1 (or similar) paper. Frame this as a hypothesis-generating area, not as established preclinical efficacy.

COVID-19, in vitro and in silico only

A 2022 paper showed by surface plasmon resonance that tuftsin binds both ACE2 and NRP-1 and prevents SARS-CoV-2 S1-protein binding to ACE2 in a competition assay. Network-pharmacology analysis identified 91 overlapping genes between tuftsin targets and COVID-19-associated genes (Huang J, Wang J, Li Y, Wang Z, Chu M, Wang Y. Front Mol Biosci. 2022;9:859162. PMID 35402510). No animal challenge model and no human trial have been conducted. The mechanism is plausible, NRP-1 is an established SARS-CoV-2 co-receptor, but the gap from SPR binding to clinical antiviral effect is enormous and unresolved.

Sepsis (2025), the most translationally important modern paper

Qing G et al. FcγR-targeted tuftsin clusters rejuvenate macrophages in preclinical sepsis-associated secondary infection. Sci Transl Med. 2025;17(830):eadv0313. PMID 41442500.

Published 24 December 2025. The “BATMAN” nanoparticle (Bacterial-lipase-Activated Tuftsin-bearing self-assembling Macrophage-Activating Nanoparticle) is engineered so that tuftsin clusters are exposed only at bacterial infection sites, where bacterial lipases trigger the unmasking. In cecal-slurry septic mice with secondary pulmonary infection, BATMAN improved survival and immune competence versus antibiotic monotherapy and versus naked tuftsin, across polymicrobial and multi-drug-resistant pathogen challenges.

This is the highest-profile tuftsin-related preclinical paper in a generation. Whether the program advances to an Investigational New Drug application remains to be seen, but methodologically it represents the most serious tuftsin-derived therapeutic candidate in decades.


Human Clinical Evidence

The honest version: there isn’t much.

ClinicalTrials.gov status (June 2026)

Zero registered studies for “tuftsin” across query.term, query.intr, query.cond, and query.titles on ClinicalTrials.gov as of 2026-06-21, via both the v2 API and the browser UI. This is itself a significant finding.

Published human therapeutic trials

The substantive PubMed-indexed human therapeutic trials of native tuftsin are:

  1. Catane R et al. Ann NY Acad Sci. 1983;419:251–60. PMID 6370073. A small Israeli (Hadassah) Phase I-level series. “Toxicology and antitumor activity of tuftsin.”
  2. Warner E, Sulkes A, Catane R et al. Chemioterapia. 1987;6(2 Suppl):706–8. PMID 2855624. Tuftsin plus cyclophosphamide in non-small-cell lung cancer. Small Israeli series; never advanced to Phase II/III. This is the most recent PubMed-indexed therapeutic trial of native tuftsin in humans, roughly 39 years ago at the time of writing.

That is the entire human therapeutic literature for native tuftsin. Two small Israeli oncology series from the 1980s, fewer than approximately 50 patients combined, and no published controlled trial since 1987.

Observational and imaging studies, frequently miscited

  • Corazza GR et al. Lancet. 1991;337(8732):12–3. PMID 1670648. “Tuftsin deficiency in AIDS.” Observational study of 21 AIDS patients, 7 ARC patients, 22 splenectomized patients, and 37 healthy controls. Tuftsin activity was significantly lower in AIDS/ARC and splenectomized groups versus healthy controls, with inverse correlation to splenic function. This is a deficiency study, not a therapy trial. It is frequently miscited as evidence that tuftsin was studied as an AIDS treatment, which is not what the paper reports.
  • Caveliers V et al. J Nucl Med. 2001;42:154–61. PMID 11197967. First-in-human dosimetry of 99mTc-RP128, a tuftsin-receptor-targeted radiotracer for inflammation imaging. Not therapeutic tuftsin.
  • Chinese clinical series on partial splenic autotransplantation in portal hypertension patients (PMIDs 11772224, 17439735, 19562997) used serum tuftsin as a biomarker of restored splenic phagocytic function. Not tuftsin therapy.

Tuftsin-deficiency syndrome

The original description was published in 1972:

Constantopoulos A, Najjar VA, Smith JW. Tuftsin deficiency: a new syndrome with defective phagocytosis. J Pediatr. 1972;80(4):564–72. PMID 4111394.

Reported in pediatric patients with severe recurrent skin, lymph node, and pulmonary infections. The familial form was described with one heterozygous parent producing affected offspring; the “autosomal recessive” inheritance label sometimes seen in secondary literature is not used verbatim in the 1972 paper, and the inheritance pattern remained debated. OMIM entry 191150 catalogs the syndrome.

Najjar’s 1975 follow-up extended the description to acquired forms after splenectomy and in infiltrative spleen disease (Najjar VA. J Pediatr. 1975;87(6 Pt 2):1121–4. PMID 1242395). Treatment has historically been γ-globulin replacement plus targeted antibiotic chemotherapy, synthetic tuftsin replacement therapy in deficiency patients has never been the subject of a published controlled trial, contrary to a commonly repeated claim.

The syndrome is extremely rare, and modern phagocyte-disorder classifications (chronic granulomatous disease, myeloperoxidase deficiency, leukocyte adhesion deficiency, and others) have largely subsumed the diagnostic space. The clinical significance today is mostly historical, tuftsin deficiency established the biological necessity of the peptide, even though the syndrome is not part of routine current pediatric immunology differentials.

Why mainstream pharma abandoned tuftsin

These reasons are documented and not controversial:

  • Plasma half-life on the order of seconds-to-minutes. Aminopeptidases (notably leucine aminopeptidase) cleave the N-terminal threonine almost immediately on intravenous administration. The unprotected tetrapeptide is one of the least pharmacokinetics-friendly bioactive peptides in the canon.
  • Modest effect sizes in murine work, almost always requiring adjuvant chemotherapy or a delivery vehicle for measurable benefit.
  • Receptor controversy. The existence of a discrete tuftsin receptor was disputed for decades; only in 2013 (PMID 24033337) was NRP-1 confirmed. This uncertainty discouraged late-1990s pharma investment.
  • No Phase II/III program ever completed for native tuftsin as a stand-alone therapeutic in any indication.
  • The analog space was largely captured by Selank (TKPR + Pro-Gly-Pro), which extends stability from seconds to roughly 30 minutes. Selank development absorbed much of the residual scientific interest in tuftsin pharmacology, although Selank itself has no FDA approval and only Russian clinical work behind it.

Dosing (Research Context Only)

There is no FDA-approved dosing for tuftsin. The figures below are research conventions, not clinical guidance.

Routes of administration

  • Intraperitoneal (IP) and intravenous (IV) dominate the rodent literature.
  • Subcutaneous (SC) is reported in derivative-pharmacokinetic papers; bioavailability of native tuftsin SC is not directly reported in the primary literature located in this research pass.
  • Oral is effectively zero bioavailability, gastric and intestinal peptidases destroy the unprotected tetrapeptide. This is the rationale for stabilized analogs such as Selank.
  • Intranasal has no primary pharmacokinetic data for native tuftsin in humans or animals. Intranasal data for Selank are not transferable to TKPR.

Doses used in published research

Animal studies (well-documented):

  • Mouse and rat IP/IV: roughly 1–20 mg/kg range across the Najjar, Fridkin, and Wleklik literature, without reported toxicity at the doses tested.
  • EAE mouse studies: typically 1–2 mg/kg IP daily (Wu et al. 2012, Thompson et al. 2018).
  • Beagle pharmacokinetic study of the “T peptide” derivative (not native tuftsin): 2, 6, and 18 mg/kg SC, with non-linear pharmacokinetics and a derivative half-life of 1.3–2.8 hours versus native tuftsin’s roughly 16-minute baseline (Gu R, He Y, Han S et al. Drug Metab Pharmacokinet. 2016. PMID 26775850).

Human dose ranges: Specific human SC doses sometimes quoted online for native tuftsin (for example, 50–500 mcg SC daily, or every-other-day protocols) cannot be sourced to a verified modern primary citation. These figures should be treated as community lore rather than established clinical guidance. In many cases, the underlying number originated from a Selank protocol and was reassigned to tuftsin in vendor copy.

Frequency

Because of the ultra-short half-life, any dosing schedule for native tuftsin is, mechanistically, a “pulse” rather than steady-state exposure. Receptor-mediated endocytosis downregulates surface NRP-1 within 10–15 minutes of exposure, then recycles (PMID 6322775). The biology arguably favors infrequent dosing with a stabilized analog over frequent dosing of the native peptide, which is part of the rationale for the modern revival of conjugate and nanoparticle approaches.

For the Peptide Toolkit calculator, the dose field is intentionally left without a confident default for native tuftsin. Treat any specific microgram figure as a research convention to be set deliberately, not as a validated clinical dose.


Reconstitution

  • Form supplied: Lyophilized free peptide or diacetate salt. Vials typically 1–10 mg.
  • Long-term storage: −20 °C lyophilized; stable for years (manufacturer-standard for short peptides). Short-term shipment at ambient temperature is acceptable.
  • Reconstitution solvent: Bacteriostatic water for injection (BWFI, 0.9% benzyl alcohol) is the standard. Sterile water for injection is acceptable for single-day use. Tuftsin is freely water-soluble, no DMSO, no organic co-solvent, no acid required. The basic Lys and Arg residues drive aqueous solubility.
  • Reconstituted-solution stability: Limited primary data exist specifically for native tuftsin in solution. The short sequence and absence of Asn, Gln, Met, Cys, or Trp residues means typical deamidation and oxidation pathways are not concerns. However, Arg-containing peptides at neutral-to-alkaline pH can show slow hydrolytic degradation. General guidance: store the reconstituted vial at 2–8 °C, use within 7–14 days, minimize freeze-thaw cycles.

For the Peptide Toolkit calculator entry, the diluent defaults to BWFI, with refrigerated reconstituted storage and a 7–14-day in-use window.


Safety Profile

Endogenous baseline

Tuftsin circulates physiologically in healthy human serum at low concentrations (200–500 ng/mL in reported series). Humans tolerate endogenous tuftsin lifelong without harm. The inverse safety argument from the deficiency syndrome (OMIM 191150) is that the absence of tuftsin causes a clinical syndrome of recurrent infections.

Animal toxicology

Mice and rats tolerated 1–20 mg/kg IP/IV without reported organ damage, mortality, or behavioral changes across multiple studies. A definitive LD50 paper for native tuftsin was not located in this research pass. Specific LD50 numbers sometimes seen in secondary sources have unit-mismatch problems and should be treated as unverified.

Clinical adverse events

The 1980s Israeli and Eastern European human series reported no significant adverse events, but those trials were small (fewer than approximately 100 patients total across all published series), uncontrolled, single-arm, not modern good-clinical-practice quality, and last published in 1987 (PMID 2855624). No modern controlled safety data exist for native tuftsin in humans. This is a material gap.

Theoretical concerns

  • Immune over-activation / cytokine storm risk. Tuftsin polarizes macrophages toward M1 in pro-inflammatory contexts and M2 via NRP-1/TGF-β in anti-inflammatory contexts. In a patient already in cytokine storm or sepsis, paradoxical effects are plausible, the BATMAN nanoparticle design (PMID 41442500) explicitly engineered around this by masking tuftsin clusters until bacterial lipases unmask them at infection sites.
  • Angiogenesis modulation. Tuftsin binds the same NRP-1 b1 pocket as VEGF; theoretical antagonism of VEGF/VEGFR signaling is possible. Clinical significance is unknown.
  • TGF-β driven immunosuppression in tumors. Canonical tuftsin signaling drives TGF-β release, which is immunosuppressive in the tumor microenvironment and pro-fibrotic in tissues. Concerning for cancer patients on checkpoint immunotherapy.

Immunogenicity

No primary publications were located documenting anti-tuftsin antibody formation in humans. Given the molecule’s tiny size (4 residues, ~501 Da) and identity with an endogenous sequence, immunogenicity would be unexpected, but this is theoretical reasoning, not evidence. The page does not claim “non-immunogenic” without sourcing.


Drug Interactions

No formal drug-drug interaction studies of tuftsin exist in primary literature. All discussion below is mechanism-based / theoretical.

Interacting classMechanismConcern
NRP-1-targeting oncology drugs (research-tool EG00229; investigational anti-NRP1 antibodies including MNRP1685A/vesencumab)Direct receptor competitionMutual antagonism; tuftsin would interfere with anti-NRP1 oncology agents
VEGF-pathway drugs (bevacizumab, ranibizumab, aflibercept)Tuftsin and VEGF compete for the same NRP-1 b1 pocket; aflibercept targets VEGF ligand, not NRP-1 directlyTheoretical; net effect unclear
Class-3 semaphorin pharmacology (Sema3A inhibitors)Class-3 semaphorins bind NRP-1Theoretical receptor competition
Immunosuppressants (cyclosporine, tacrolimus, rituximab, adalimumab, anti-TNF biologics)Tuftsin’s macrophage activation would mechanistically oppose immunosuppressionTheoretical mutual antagonism; no clinical data
Other immunostimulants (thymosin α-1, interferons, GM-CSF, LL-37)Additive macrophage and phagocyte activationTheoretical additive effect; commonly stacked in community biohacking without published data
TGF-β inhibitors (galunisertib, fresolimumab)Tuftsin’s main downstream effect is TGF-β releaseMutual mechanistic opposition

For a fuller treatment of interaction risk see the Peptide Interactions page. Tuftsin appears there coded as mechanism-based / theoretical interactions only, with the strongest mechanism-based caution flagged for concomitant use with anti-NRP1 oncology drugs and TGF-β pathway inhibitors.


Regulatory Status (United States, June 2026)

Tuftsin is NOT FDA-approved for any indication. No NDA or BLA is on file. No marketed drug product in the US contains tuftsin as the active ingredient. There is no Orphan Drug, Fast Track, Breakthrough, or Regenerative Medicine Advanced Therapy designation.

  • Zero studies registered on ClinicalTrials.gov as of 2026-06-21.
  • No active IND that this research pass could identify.
  • No publicly announced sponsor program for native tuftsin.

Tuftsin is NOT on the FDA 503A Bulks List and was NOT among the 12 peptides FDA removed from Category 2 on April 15, 2026. The April 2026 removal list comprised BPC-157, LL-37, DiHexa, DSIP (Emideltide), Epitalon, GHK-Cu (injectable only), KPV, PEG-MGF, Melanotan II, MOTS-C, Semax, and TB-500. Tuftsin was not on that list.

Tuftsin is also not on the July 23–24, 2026 PCAC agenda (which covers BPC-157, KPV, TB-500, MOTS-C, Emideltide, Semax, and Epitalon) and is not on the announced February 2027 review agenda.

Tuftsin is not a controlled substance. It does not appear in 21 CFR 1308 schedules.

Endogenous status does not equal approval. Tuftsin is produced naturally in every human as a metabolite of IgG (it is endogenous in everyone’s serum at 200–500 ng/mL). However, the synthetic version sold by chemical suppliers is classified as a research chemical, labeled “for laboratory research use only, not for human consumption.” Endogenous origin does not confer FDA-approved status on the synthetic supply.

Practical compounding implication. Because tuftsin is (a) not the active ingredient of any FDA-approved drug, (b) not the subject of a USP/NF monograph, and (c) not on the 503A Bulks List, a 503A compounding pharmacy cannot lawfully use tuftsin as a bulk drug substance for compounded preparations dispensed to US patients. Any “compounded tuftsin” sold to US patients is operating outside the lawful 503A framework.


Honest Framing, What This Adds Up To

Tuftsin is the molecular ancestor of better-known descendants (Selank above all), the first peptide isolated from IgG, and the canonical example of an endogenous immunomodulatory fragment. The biology is real, the receptor is identified, and the 2025 Sci Transl Med BATMAN paper marks the most credible translational tuftsin work since the 1980s.

The clinical record, by contrast, is sparse: two small Israeli oncology series from 1983 and 1987, fewer than approximately 50 patients combined, no PubMed-indexed therapeutic trial of native tuftsin since 1987, and zero studies currently registered on ClinicalTrials.gov. The synthetic peptide sold by chemical suppliers is research-grade material, not an FDA-approved therapeutic.

If you are searching for “tuftsin” because of a stack recommendation or a vendor product page, the most useful thing this guide can do is point at what is actually known versus what is community lore. The mechanism is well-mapped. The pharmacokinetics are unforgiving. The human therapeutic data is essentially empty. The current scientific interest is in engineering around the half-life problem (nanoparticles, fusion proteins, the Selank tail), not in giving naked TKPR to people.


  • Thymulin, a thymic peptide with overlapping macrophage-activation biology and a similarly thin clinical record.
  • Splenopentin, a splenic immunomodulatory pentapeptide with a related mechanistic position.
  • LL-37, the human cathelicidin antimicrobial peptide; mechanistically distinct (membrane disruption + immunomodulation) but commonly compared in immune-support stacks.
  • Where to Buy Tuftsin, editorial guidance on research-grade chemical supplier sourcing.
  • Peptide Interactions, tuftsin’s mechanism-based theoretical interactions in context.

Verification note: All PMID author attributions in this draft were cross-checked against the RESEARCH-tuftsin.md audit header corrections dated 2026-06-21. PMIDs 35402510, 8188392, 26880314, 26775850, and 31702807 use the corrected authorships from the audit header (Huang J et al.; Cillari E et al.; Nissen JC and Tsirka SE; Gu R et al.; Bao Z et al., respectively), not the body-text attributions that appeared in earlier drafts of the dossier. PMID 7982035 (Martínez Cairo Cueto et al.) is not cited in the body of this guide; the modern 289–292 IgG residue position is anchored to PMID 36875797 (Yuan D et al. 2023) instead.

Get peptide updates

Monthly peptide updates and FDA alerts. No spam, unsubscribe anytime.

Cycle Lengths

Cycling summary: No established cycling protocol for this peptide in the published literature. Community protocols vary; consult a compounding-focused clinician for a personalized plan.

Cycle timing should be informed by the peptide’s half-life, receptor tachyphylaxis profile (if applicable), and personal response monitored through lab work. Log both on-cycle and off-cycle biomarkers to understand recovery kinetics.

Lab Monitoring

Tuftsin is a research-tier healing peptide with no established peripheral efficacy biomarker. Lab monitoring should be prudent general-health surveillance rather than efficacy tracking. The panels below cover organ systems most relevant during peptide research use.

Baseline (before starting): CBC with differential, comprehensive metabolic panel (CMP) covering LFTs and renal function, fasting lipid panel, hs-CRP for inflammatory baseline, fasting glucose, and HbA1c if metabolic risk factors are present. Age-appropriate cancer screening is prudent given rodent-only data on healing/angiogenic activity for most research peptides in this class.

During use: repeat CMP + CBC every 8-12 weeks. Repeat hs-CRP alongside if using for inflammatory conditions to track the inflammatory read against symptom response. Watch trends in ALT/AST (liver) and eGFR (renal) rather than single readings.

What to flag to a physician: injection-site erythema or nodule formation, unexplained weight changes, new joint or mass symptoms, any lab value trending outside reference range across two consecutive draws.

For the full class-wide monitoring framework and a plain-language comparison of DTC lab services for peptide users, see the Peptide Lab Testing pillar guide.

Storage & Travel

Storage

Lyophilized powder: Lyophilized powder freezer -20°C (-4°F) for long-term storage; stable at room temperature for shipping and short-term handling.

Reconstituted: Refrigerate reconstituted vial at 2-8°C (36-46°F); use within ~28 days per USP <797> peptide stability guidance. Never freeze a reconstituted vial, since freeze-thaw cycles damage peptide bonds and reduce potency.

Travel

Domestic flights: pack reconstituted vials in an insulated cooler with reusable ice packs. The TSA 3-1-1 rule limits liquids to 100 mL per container in carry-on; a 3-5 mL peptide vial passes with room to spare. Keep pharmacy or vendor documentation visible for TSA questions. Lyophilized powder in original sealed vial does not require cooling for short trips.

International travel: Tuftsin is a research peptide in most jurisdictions with varying import restrictions — check the destination country’s rules before travel. Carry a physician’s letter if the peptide was prescribed by a compounding-focused clinician.

Road trips: keep the cooler in the cabin, not the trunk, during summer. Hotel mini-fridges vary in temperature stability; an insulated bag inside the mini-fridge adds a buffer.

Emergency out-of-fridge: reconstituted Tuftsin at room temperature under 24 hours is generally still viable per USP stability guidance. Longer excursions or temperatures above 30°C compromise potency; discard and reconstitute a fresh vial.

Similar Posts